TNXP at a glance
Tonix Pharmaceuticals Holding Corp. (TNXP, SEC CIK 1430306) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Tonix Pharmaceuticals Holding Corp. (TNXP) reported revenue of $13.1 million (up 29.8% from FY2024) and a net loss of $124.0 million. Diluted EPS was -$14.57.
- As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Tonix Pharmaceuticals Holding Corp. (TNXP) shares worth $49.2 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by LEDERMAN SETH on November 11, 2026 of 5,000 shares at $4.05 per share.
- In the last 90 days, TNXP insiders reported 2 open-market purchases ($48K) and 0 open-market sales ($0) on Form 4, a net purchase of $48K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $13.1M
- +29.8% vs prior year
- Insiders · 90 days
- 2 buys · 0 sells
- Net +$48K
- 13F holders
- 23 funds
- $49.2M · +2 vs prior quarter
- Latest 8-K
- Nov 13, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New legal risk: DRL’s October 1, 2026 paragraph IV challenge to four TONMYA patents expiring March 14, 2034
- Patent litigation deadline: 45 days to seek the 30-month FDA approval stay
- Revenue risk: Generic TONMYA could reduce sales volume and pricing after regulatory exclusivity expires in August 2028
- New operational risk: AI inaccuracies could misdirect resources or delay development and regulatory submissions
- New compliance risk: Evolving AI laws may increase compliance costs or limit acceptance of AI-supported analyses
Management Discussion & Analysis
- Quarterly revenue $17.2M, up from $3.3M YoY, driven by TONMYA launch
- TONMYA revenue $15.0M, versus Zembrace SymTouch $1.5M and $2.6M YoY
- Operating loss $55.4M vs $33.1M; net loss $53.3M vs $32.0M YoY
- Cash $162.8M; operating cash used $125.6M, financing provided $82.0M through nine months
- Resources expected to last into early third quarter 2027, with additional funding required; going-concern substantial doubt
AI summary of the TNXP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- DRL filed a Paragraph IV ANDA challenging four Orange Book patents covering TONMYA 2.8 mg
- Tonix sued DRL for patent infringement in New Jersey on November 13, 2026
Item 2.02: Results of Operations and Financial Condition
- Tonix announced operating results for the quarter ended September 30, 2026
- Detailed financial figures and management commentary are in Exhibit 99.01, the accompanying earnings release
Item EX-99.1: Item EX-99.1
- TONMYA net sales reached approximately $15.0 million, up 37% quarter-over-quarter, with prescriptions up 28% to 16,375
- Coverage expanded to approximately 166 million lives, or 53% of U.S. covered lives, supporting commercial traction
Item 8.01: Other Events
- Item 8.01 incorporates the Item 2.02 earnings disclosure by reference
- Investor focus remains on the separate Item 2.02 exhibit for financial results or operating updates
Item 2.02: Results of Operations and Financial Condition
- Preliminary Q3 2026 TONMYA net revenue estimated at $14.0 million to $15.0 million
- Cash and cash equivalents approximately $162.8 million as of September 30, 2026
AI summaries of TNXP 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TNXP
Don't miss the next TNXP filing
- Alerts as it files. A push when TNXP files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TNXP, by share count.
- Ask anything. An AI agent that reads every TNXP filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| LEDERMAN SETH | Buy | Nov 11, 2026 | 5,000 | $4.05 |
| LEDERMAN SETH | Buy | Aug 27, 2026 | 2,000 | $13.79 |
| BAGGER RICHARD H | Buy | Aug 20, 2026 | 1,000 | $12.60 |
| SAENGER BRADLEY | J | Jun 30, 2026 | 1,453 | $10.91 |
| Taylor Carolyn E. | Buy | Jun 12, 2026 | 1,415 | $10.55 |
| LEDERMAN SETH | Buy | Jun 9, 2026 | 5,000 | $11.79 |
| Stillwell Richard Newcomb | Buy | Jun 8, 2026 | 5,000 | $11.65 |
| Taylor Carolyn E. | A | May 12, 2026 | 22,700 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $10.1M | $13.1M |
| Operating Income | -$118.4M | -$136.7M | -$125.7M |
| Net Income | -$116.7M | -$130.0M | -$124.0M |
| Op. Margin | - | -1354.3% | -959.1% |
| Net Margin | - | -1288.3% | -946.2% |
| Balance Sheet | |||
| Total Assets | - | $162.9M | $277.2M |
| Equity | - | $139.6M | $245.2M |
| ROE | - | -93.2% | -50.6% |
| Per Share | |||
| EPS | - | $-176.60 | $-14.57 |
| Cash Flow | |||
| Operating CF | -$102.0M | -$60.9M | -$99.8M |
| CapEx | $7.9M | $120K | $3.4M |
Source: XBRL data in Tonix Pharmaceuticals Holding Corp. (TNXP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate TNXP share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 23 | $49.2M |
| Q2 2026 | 21 | $64.6M |
| Q1 2026 | 18 | $40.6M |
| Q4 2025 | 16 | $33.8M |
| Q3 2025 | 13 | $41.7M |
| Q2 2025 | 15 | $34.6M |
| Q1 2025 | 7 | $3.3M |
- BlackRock+165.1K (+12%)
- Citadel Advisors LLC+141.6K (+72%)
- State Street Corp+63.7K (+23%)
- Vanguard Portfolio Management LLC+14.2K (+15%)
- Invesco Ltd+13.3K (+35%)
- AQR Capital Management−211.8K (-24%)
- Millennium Management−148.2K (-15%)
- Bank of America Corp−35.3K (-58%)
- Wells Fargo & Co−9.0K (-58%)
- Citigroup−5.9K (-88%)
- D.E. Shaw & Co+35.3K
- Raymond James Financial+15.2K
- Prudential Financial+13.4K
- FMR LLC (Fidelity)−93.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 113 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TNXP filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 13, 2026 | - | Analysis | - |
| 4 | Nov 12, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 15, 2026 | - | Analysis | - |
| 8-K | Oct 2, 2026 | - | Analysis | - |
| 8-K | Sep 22, 2026 | - | Analysis | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 4 | Aug 31, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 8-K | Aug 18, 2026 | - | Analysis | - |
| SC 13G | Aug 13, 2026 | - | - | |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Jul 21, 2026 | - | Analysis | - |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| 4 | Jul 9, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| SC 13G | Jun 15, 2026 | - | - | |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - | |
| 8-K | Jun 8, 2026 | - | - | |
| 8-K | May 27, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
TNXP SEC filings: frequently asked questions
Are TNXP insiders buying or selling?
In the last 90 days, Tonix Pharmaceuticals Holding Corp. (TNXP) officers, directors and 10% owners reported 2 open-market purchases worth $47,855 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TNXP stock?
As of September 30, 2026, the largest Tonix Pharmaceuticals Holding Corp. (TNXP) holders among the 13F filers tracked by SignalX were BlackRock ($15.2 million), Millennium Management ($8.0 million), Vanguard Capital Management LLC ($6.7 million), AQR Capital Management ($6.5 million), Citadel Advisors LLC ($3.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TNXP's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Tonix Pharmaceuticals Holding Corp. (TNXP) reported revenue of $13.1 million (up 29.8% from FY2024) and a net loss of $124.0 million. Diluted EPS was -$14.57. The figures come from the XBRL data in the 10-K.
What did TNXP report in its latest 8-K?
Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K on November 13, 2026 reporting Item 8.01 (Other Events). DRL filed a Paragraph IV ANDA challenging four Orange Book patents covering TONMYA 2.8 mg.
What are the latest TNXP SEC filings?
Tonix Pharmaceuticals Holding Corp. (TNXP) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on November 12, 2026.
What is TNXP's SEC CIK number?
Tonix Pharmaceuticals Holding Corp. (TNXP)'s SEC Central Index Key (CIK) is 1430306. EDGAR lists every TNXP filing under that number.
Ask anything about TNXP
The research agent reads TNXP's filings, financials, insider trades and 13F holders, then answers with sources.